Nephrol Dial Transplant (2000) 15: 8-10
© 2000 European Renal Association-European Dialysis and Transplant Association
Editorial Comments
Hypertension and allograft nephropathy—cause, consequence, or both?
Department of Nephrology and Internal Intensive Care Medicine, Universitätsklinikum Charité, Campus Virchow Klinikum, Humboldt University, Berlin, Germany
Correspondence and offprint requests to: Ralf Schindler, MD, Department of Nephrology, Universitätsklinikum Charité, Campus Virchow Klinikum, Augustenburger Platz 1, D-13353 Berlin, Germany.
Hypertension is a risk factor for chronic allograft nephropathy
Chronic graft loss is one of the biggest problems after renal transplantation. Data from the United States Renal Data System [1] indicate that the projected median half life of renal allografts has been steadily improving over the past years, from 5.2 years in 1986–1987 to 10.2 years in 1994–1995. However, approximately 5% of renal transplants are lost every year. An ill defined entity called chronic rejection or chronic allograft nephropathy (CAN) remains the leading cause of graft loss after the first year of transplantation, particularly if death with a functioning graft is excluded as a cause of late graft failure [2]. Traditionally, the causes of CAN have been divided
Hypertension: cause or consequence of chronic allograft nephropathy?
Interaction between immunological and non-immunological factors in the pathogenesis of chronic allograft nephropathy
Clinical consequences
Acknowledgments
References
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. G. Pradel, R. Jain, C. D. Mullins, J. A. Vassalotti, and S. T. Bartlett A Survey of Nephrologists' Views on Preemptive Transplantation Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(6): 1837 - 1845. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Miller The Role of Bone Biopsy in Patients with Chronic Renal Failure Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(Supplement_3): S140 - S150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-Y. Jungers, C. Robino, G. Choukroun, T. Nguyen-Khoa, Z. A. Massy, and P. Jungers Incidence of anaemia, and use of epoetin therapy in pre-dialysis patients: a prospective study in 403 patients Nephrol. Dial. Transplant., September 1, 2002; 17(9): 1621 - 1627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Schratzberger and G. Mayer Chronic allograft failure: a disease we don't understand and can't cure? Nephrol. Dial. Transplant., August 1, 2002; 17(8): 1384 - 1390. [Full Text] [PDF]
|
|
|
|
|
|
G. B. Piccoli, G. Grassi, E. Mezza, M. Gai, C. Iacuzzo, F. Bechis, L. Biancone, A. Jeantet, F. Dani, P. C. Perin, et al. Early referral of Type 2 diabetic patients: are we ready for the assault? Nephrol. Dial. Transplant., July 1, 2002; 17(7): 1241 - 1247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Jungers Late referral: loss of chance for the patient, loss of money for society Nephrol. Dial. Transplant., March 1, 2002; 17(3): 371 - 375. [Full Text] [PDF]
|
|
|
|
 |
|
 S. J Davies Review: The epidemic of diabetic renal disease -- the practical challenges for renal replacement programmes The British Journal of Diabetes & Vascular Disease, March 1, 2002; 2(2): 86 - 89. [Abstract] [PDF]
|
|
|
|
|
|
P. Jungers, Z. A. Massy, T. Nguyen-Khoa, G. Choukroun, C. Robino, F. Fakhouri, M. Touam, A.-T. Nguyen, and J.-P. Grunfeld Longer duration of predialysis nephrological care is associated with improved long-term survival of dialysis patients Nephrol. Dial. Transplant., December 1, 2001; 16(12): 2357 - 2364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-U. Eckardt After 15 years of success--perspectives of erythropoietin therapy Nephrol. Dial. Transplant., September 1, 2001; 16(9): 1745 - 1749. [Full Text] [PDF]
|
|